Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
The mdm2 oncogene product, MDM2, is an ubiquitin protein ligase that inhibits the transcriptional activity of the tumor suppressor p53 and promotes its degradation. About 50% of all human cancers present mutations or deletions in the TP53 gene. In the remaining half of all human neoplasias that express the wild-type protein, aberrations of p53 regulators, such as MDM2, account for p53 inhibition. For this reason, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction is a promising strategy for the treatment of cancers retaining wild-type p53. The development of inhibitors has been challenging. Although many small-molecule MDM2 inhibitors have shown potent in vitro activity, only a limited number of compounds have demonstrated to possess acceptable pharmacokinetic properties for in vivo evaluation. To date, the most studied chemotypes have been cis-imidazolines (such as nutlins), benzodiazepines, and spiro-oxindoles. The cis-imidazolines were the first discovered potent and selective small-molecule inhibitors of the p53-MDM2 interaction and they continue to show therapeutic potential. This review will focus on recent molecular modeling approaches (molecular dynamics, pharmacophore-based, molecular docking, structure-based design) used with the aim to better understand the behavior of these proteins and to discover new small-molecule inhibitors of the p53-MDM2 protein-protein interaction for the treatment of cancer.
Lauria
A
A
Dipartimento Farmacochimico, Tossicologico e Biologico, Università di Palermo, Palermo, Italy.
Tutone
M
M
Ippolito
M
M
Pantano
L
L
Almerico
A M
AM
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D001570:Benzodiazepinones / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D048288:Imidazolines / Q000737:chemistry / Q000627:therapeutic use; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use; D056004:Molecular Dynamics Simulation; D009369:Neoplasms / Q000188:drug therapy; D000078183:Oxindoles; D017434:Protein Structure, Tertiary; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000970:Antineoplastic Agents; D001570:Benzodiazepinones; D048288:Imidazolines; D007211:Indoles; D000078183:Oxindoles; D016159:Tumor Suppressor Protein p53; C022960:2-oxindole; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2